Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioAge Labs (BIOA) Cash & Current Investments (2023 - 2026)

BioAge Labs' Cash & Current Investments history spans 3 years, with the latest figure at $281.1 million for Q4 2025.

  • On a quarterly basis, Cash & Current Investments fell 20.67% to $281.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $281.1 million, a 20.67% decrease, with the full-year FY2025 number at $281.1 million, down 20.67% from a year prior.
  • Cash & Current Investments hit $281.1 million in Q4 2025 for BioAge Labs, down from $285.8 million in the prior quarter.
  • Over the last five years, Cash & Current Investments for BIOA hit a ceiling of $354.3 million in Q4 2024 and a floor of $25.0 million in Q4 2023.
  • Historically, Cash & Current Investments has averaged $259.0 million across 3 years, with a median of $291.4 million in 2025.
  • Biggest five-year swings in Cash & Current Investments: soared 1319.84% in 2024 and later decreased 20.67% in 2025.
  • Tracing BIOA's Cash & Current Investments over 3 years: stood at $25.0 million in 2023, then soared by 1319.84% to $354.3 million in 2024, then decreased by 20.67% to $281.1 million in 2025.
  • Business Quant data shows Cash & Current Investments for BIOA at $281.1 million in Q4 2025, $285.8 million in Q3 2025, and $297.0 million in Q2 2025.